Spain Breast Cancer Drugs Market Size & Outlook, 2023-2030

The breast cancer drugs in Spain is expected to reach a projected revenue of US$ 331.8 million by 2030. A compound annual growth rate of 6.2% is expected of Spain breast cancer drugs from 2024 to 2030.
Revenue, 2023 (US$M)
$217.9
Forecast, 2030 (US$M)
$331.8
CAGR, 2024 - 2030
6.2%
Report Coverage
Spain

Spain breast cancer drugs highlights

  • The Spain breast cancer drugs generated a revenue of USD 217.9 million in 2023 and is expected to reach USD 331.8 million by 2030.
  • The Spain market is expected to grow at a CAGR of 6.2% from 2024 to 2030.
  • In terms of segment, targeted therapy was the largest revenue generating therapy in 2023.
  • Immunotherapy is the most lucrative therapy segment registering the fastest growth during the forecast period.


Breast cancer drugs data book summary

Market revenue in 2023USD 217.9 million
Market revenue in 2030USD 331.8 million
Growth rate6.2% (CAGR from 2023 to 2030)
Largest segmentTargeted therapy
Fastest growing segmentImmunotherapy
Historical data2018 - 2022
Base year2023
Forecast period2024 - 2030
Quantitative unitsRevenue in USD million
Market segmentationChemotherapy, Immunotherapy, Targeted Therapy, Hormonal Therapy
Key market players worldwideNovartis AG ADR, Pfizer Inc, Merck KGaA, Janssen Pharmaceuticals, Celgene, Roche Holding AG, AstraZeneca PLC, AbbVie Inc, Bristol-Myers Squibb Co, Macrogenics Inc, Celldex Therapeutics Inc, Sanofi SA, Amgen Inc


Other key industry trends

  • In terms of revenue, Spain accounted for 2.5% of the global breast cancer drugs in 2023.
  • Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
  • In Europe, Germany breast cancer drugs is projected to lead the regional market in terms of revenue in 2030.
  • Denmark is the fastest growing regional market in Europe and is projected to reach USD 76.7 million by 2030.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Breast Cancer Drugs Companies

Name Profile # Employees HQ Website

Spain breast cancer drugs outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to breast cancer drugs will help companies and investors design strategic landscapes.


Targeted therapy was the largest segment with a revenue share of 64.2% in 2023. Horizon Databook has segmented the Spain breast cancer drugs based on chemotherapy, immunotherapy, targeted therapy, hormonal therapy covering the revenue growth of each sub-segment from 2018 to 2030.


The Spanish breast cancer drugs market is still in its premature stage. According to data published by the WHO in 2018, around 32,825 new breast cancer cases were recorded. In addition, increasing mortality due to breast cancer is considered to be another factor aiding growth.

According to data by Statistica, from 2005 to 2017, the annual number of deaths due to this cancer has increased from 5,792 to 6,573 in Spain. Increasing awareness about cancer is another driving factor; for instance, SAFFRON, which supports the fight against breast cancer, in collaboration with the Spanish Cancer Association is working toward increasing awareness.

Reasons to subscribe to Spain breast cancer drugs databook:

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of Spain breast cancer drugs databook

  • Our clientele includes a mix of breast cancer drugs companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of country-level data and insights on the Spain breast cancer drugs, including forecasts for subscribers. This country databook contains high-level insights into Spain breast cancer drugs from 2018 to 2030, including revenue numbers, major trends, and company profiles.

Partial client list

  • logo

Spain breast cancer drugs market size, by therapy, 2018-2030 (US$M)

Spain Breast Cancer Drugs Share, 2023 & 2030 (US$M)

Spain breast cancer drugs market size, by therapy, 2018-2030 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more